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The use of heat shock protein 90 (Hsp90) inhibitors is an attractive antineoplastic therapy. We wanted to compare the
effects of the benzoquinone 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) and the novel isoxazole
resorcinol–based Hsp90 inhibitor NVP-AUY922 in a panel of pancreatic and colorectal carcinoma cell lines and in
colorectal primary cultures derived from tumors excised to patients. PANC-1, CFPAC-1, andCaco-2 cellswere intrinsically
resistant to 17-AAG but sensitive to NVP-AUY922. Other cellular models were sensitive to both inhibitors. Human
epidermal growth factor receptor receptors and their downstream signaling pathways were downregulated in
susceptible cellular models, and concurrently, Hsp70 was induced. Intrinsic resistance to 17-AAG did not correlate with
expressionof ATP-binding cassette transporters involved inmultidrug resistance. Some17-AAG-resistant, NVP-AUY922–
sensitive cell lines lacked NAD(P)H:quinone oxidoreductase 1 (NQO1) enzyme and activity. However, colorectal LoVo
cells still responded to both drugs in spite of having undetectable levels and activity of NQO1. Pharmacological and
biologic inhibition of NQO1 did not confer resistance to 17-AAG in sensitive cell lines. Therefore, even though 17-AAG
sensitivity is related to NQO1 protein levels and enzymatic activity, the absence of NQO1 does not necessarily convey
resistance to 17-AAG in these cellularmodels.Moreover,NVP-AUY922doesnot requireNQO1 for its action and is amore
potent inhibitor than 17-AAG in these cells. More importantly, we show in this report that NVP-AUY922 potentiates the
inhibitory effects of chemotherapeutic agents, such asgemcitabineor oxaliplatin, andother drugs that are currently being
evaluated in clinical trials as antitumor agents.
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The heat shock protein 90 (Hsp90) multichaperone complex plays
important roles in malignant transformation and therefore is a
promising target for cancer therapy. The Hsp90 machinery mediates
the folding, maturation, activation, and assembly of various proteins
involved in signal transduction, transcriptional regulation, and cell
cycle control [1]. Many of these client proteins are oncogenic.
Therefore, a great advantage of the use of Hsp90 inhibitors is that
multiple key oncogenic proteins can be disrupted simultaneously [2].
The geldanamycin derivative 17-allylamino-17-demethoxygeldanamycin
(17-AAG), or tanespimycin, was the first Hsp90 inhibitor that
entered clinical trials [3]. There are now about 14 inhibitors of
Hsp90 function undergoing clinical trials, which belong to different
structural classes [4]. All of them bind to a conserved pocket in the
NH2-terminal ATP-binding domain of Hsp90, inhibiting its activity.
Geldanamycin and its derivatives belong to the benzoquinone
ansamycin class, which was found to inhibit expression of the
oncogene c-myc [5] and to cause inactivation [6] and degradation of
the tyrosine kinase src [7], human EGFR 2 (HER2)/Neu [8], raf [9],
and mutated p53 [10]. However, albeit most of phase I and phase II
clinical trials with geldanamycin derivatives have already been
completed or terminated due to clinical limitations, these drugs
have proved the successful targeting of Hsp90, paving the way for the
development of second-generation Hsp90 inhibitors [11], such as
synthetic and small molecules, targeted also against the N-terminal
ATP-binding site. One class of such small inhibitors is based on the
pyrazole or resorcinol subunit, another class on the purine-scaffold,
and lastly, novel C-terminal domain–based Hsp90 inhibitors are
being developed as well [12]. NVP-AUY922 is a novel resorcinylic
isoxazole–based Hsp90 inhibitor that has shown potent preclinical
activity in cancer models [13] and in xenografts [14]. In addition, it
has shown tolerability in a phase I clinical trial [15]. The Hsp90-
client cycle involves the association and dissociation of several
cochaperones and is driven by the ATP-binding state of Hsp90 [2].
Thus, Hsp90 participates in two multichaperoning complexes with
opposing activities: ATP-bound (mature) and ADP-bound (interme-
diate). A client protein initially associates with Hsp70/Hsp40 and is
loaded onto Hsp90 through p60Hop, forming the ADP-bound
intermediate state. When ADP is transformed into ATP, the Hsp90
complex conformation is altered, releasing Hsp70/Hsp40 and p60Hop,
allowing other cochaperones such as p23, p50cdc37, and immunophilins
to bind Hsp90, forming the mature complex. Then, at this stage,
Hsp90-bound ATP is hydrolyzed, and the energy released enables client
protein folding. Hsp90 inhibitors such as 17-AAG inhibit the ATPase
intrinsic activity of Hsp90, impeding the chaperone to achieve the
mature state [16]. Consequently, a ubiquitin ligase is recruited to
the intermediate state, and a plethora of protein clients is targeted
to degradation (see http://www.picard.ch/downloads for a list of
Hsp90 interactors).
Chemoresistance is a common cause of failure to antitumor agents.
Resistance to cytotoxic compounds is associated with cross-resistance to
different drugs with or without structural similarity to the primary
agent. This pleiotropic phenomenon is known as multidrug resistance
(MDR) [17]. Although several mechanisms could be involved in the
acquisition of this phenotype, the role of P-glycoprotein (Pgp), a
member of the ATP-binding cassette (ABC) transporter family, has
been well established [18–20]. Pgp, encoded by the gene MDR1,
was first identified as a consequence of its overexpression in multidrug-
resistant tumor cells, where it mediates the ATP-dependent efflux of ahave been associated with resistance to Hsp90 inhibitors [22]. Other
ABC transporters that confer MDR phenotype are MDR-associated
protein 1 (MRP1) [23] and breast cancer resistance protein 1 (BCRP1)
[24]. The benzoquinone ansamycin class of inhibitors can be reduced to
semiquinone and hydroquinone forms through the activity of the two-
electron NAD(P)H:quinone oxidoreductase 1 (NQO1)/DT-diaphorase.
The hydroquinone forms of 17-AAG and 17-DMAGaremore stable and
more potent than their quinone partners. Chemoresistance can be
intrinsic when existing before the treatment or acquired when it is
developed during the treatment. Low levels of NQO1 have been
associated to intrinsic resistance to ansamycins [22,25] and to acquired
resistance to 17-AAG [26].
Pancreatic cancer is the fourth leading cause of cancer death in both
men and women, with most patients dying within a year [27], and
had an increasing incident rate over the last 10 years [28]. Therefore,
efforts to find novel therapeutics to fight this disease are challenging.
Colorectal carcinoma is the third most prevalent type of cancer in
men, the second most frequent type of cancer diagnosed in women
[29], and the second leading cause of cancer death [30]. These types
of cancer are highly dependent on the epidermal growth factor
receptor (EGFR) signaling pathway. Overexpression of EGFR is
common in pancreatic adenocarcinoma [31] and novel therapies in
metastatic colorectal cancer include antibodies targeted against the
EGFR, such as panitumumab and cetuximab [32]. EGFR belongs to
the HER family of transmembrane tyrosine kinase receptors, which
include HER2 (ErbB2/Neu), HER3 (ErbB3), and HER4 (ErbB4).
Upon ligand binding, EGFR undergoes a conformational change that
results in homodimerization and/or heterodimerization with the
other members of the family [33,34], which produces activation of
the receptor tyrosine kinase, which, in turn, phosphorylates tyrosine
residues on several adaptor molecules. Thus, HER receptors
transduce a downstream signal either through the extracellular
signal–regulated kinase/mitogen-activated kinase (MAPK) pathway
or the phosphatidylinositol 3-kinase/Akt pathway, involved in cellular
processes such as proliferation and survival [35].
In this report, we sought to determine the effects of 17-AAG and
NVP-AUY922 in a panel of pancreatic exocrine adenocarcinoma and
colorectal carcinoma cell lines and in colorectal primary cultures
derived from tumors excised to patients to find predictive markers of
response to such Hsp90 inhibitors, aiming at down-regulation of
signaling pathways initiated by HER receptors. We have found some
cell lines resistant to 17-AAG but still responsive to NVP-AUY922.
We have determined that ABC transporters such as Pgp (Mdr-1),
MRP1, and BCRP1 are not involved in 17-AAG resistance and that
although the absence of NQO1 is a feature of several pancreatic and
colorectal resistant cancer cell lines, its depletion is not enough to
generate a resistance phenotype to 17-AAG. Moreover, NQO1 is
related to resistance only to 17-AAG but not to other nonbenzoqui-
none Hsp90 inhibitors such as NVP-AUY922, which is a more
potent inhibitor in these cellular models. Indeed, we demonstrate in
this report that NVP-AUY922 is able to potentiate the effect of other
antitumor drugs in cells that do not respond to these agents.
Materials and Methods
Reagents
17-AAG (tanespimycin), NVP-AUY922, AZD6244, and NVP-
BEZ235 were purchased from ChemieTek (Indianapolis, IN) and
592 Comparative Study of 17-AAG and NVP-AUY922 Mayor-López et al. Translational Oncology Vol. 7, No. 5, 2014ES936 and gemcitabine from Tocris Bioscience (Bristol, United
Kingdom), and each one of them is dissolved in DMSO or
water. Propidium iodide, crystal violet, iodonitrotetrazolium
violet, 4-hydroxycoumarin (dicumarol), 2,6-dichlorophenol-
indophenol (DCPIP), and oxaliplatin were purchased from
Sigma-Aldrich (St Louis, MO).
Cell Culture
The human pancreatic carcinoma cell lines Hs 766 T, BxPC-3,
HPAF-II, CFPAC-1, PANC-1, IMIM-PC-1, IMIM-PC-2, and
RWP-1, the human colorectal carcinoma cell lines HT-29, SW620,
SW480, HCT-15, HCT 116, LoVo, Caco-2, DLD-1, LS 174 T,
and Colo 320 HSR (Colo 320), and the glioblastoma cell line
T98G were obtained from the American Type Culture Collection
(Manassas, VA) or the IMIM cell line repository (Instituto Hospital
del Mar de Investigaciones Médicas (IMIM), Barcelona, Spain).
The HGUE-C-1 cell line was kindly donated by Dr Miguel Saceda
(Hospital General Universitario de Elche, Elche, Spain). Primary
cell culture samples were obtained from colorectal tumors excised
to patients at the Hospital Clínico Universitario Virgen de la
Arrixaca (Murcia, Spain) or the Hospital General Universitario
Santa Lucía (Cartagena, Spain). Surgical samples were digested
with 1.5 U/ml dispase, 0.09 mg/ml collagenase II, 0.1 mg/ml
pronase E, and 45 U/ml hyaluronidase and incubated at 37°C for
30 minutes. Fragments were incubated with RBC lysis solution
(GeneAll Biotechnology, Seoul, Korea) for 10 minutes to eliminate
erythrocytes, washed with phosphate-buffered saline (PBS) filtered
through a 70-μm mesh, washed with PBS and harvested in
Dulbecco's modified Eagle's medium–F12 containing 20% heat-
inactivated FBS, 2 mM glutamine, 10 μg/ml insulin–5.5 μg/ml
transferrin–6.7 ng/ml selenium, 0.5 μg/ml hydrocortisone, 20 ng/
ml epidermal growth factor, 1 mM sodium pyruvate, 10 mM
Hepes, 50 units/ml penicillin, 50 mg/ml streptomycin, 2.5 μg/ml
amphotericin B, and 50 μg/ml gentamicin. Cell lines were
maintained in Dulbecco's modified Eagle's medium and
supplemented with 10% heat-inactivated FBS, 2 mM glutamine,
1 mM sodium pyruvate, 10 mM Hepes, 50 units/ml penicillin,
and 50 mg/ml streptomycin and incubated at 37°C in a
humidified 5% CO2/air atmosphere.
Cell Proliferation Assays
Cells were seeded in 96-well plates at a density of 1500 to 2500
cells per well and treated with vehicle or different concentrations of
drugs for 3 days in sextuplicate. Then, cells were washed with PBS,
fixed with 4% formaldehyde, and stained with 0.05% crystal violet
for 30 minutes at room temperature. Cells were then washed three
times with deionized water, and the wells were completely dried for
at least 30 minutes. Cells were lysed with 0.1 M HCl and
absorbance was determined at 620 nm in a microplate reader
(Infinite M200PRO NanoQuant; Tecan Group, Männedorf,
Switzerland). Viability of cells was monitored using the trypan
blue dye exclusion method.
Colony Formation (Soft Agar Assays)
Cells were suspended in 0.36% agar with appropriate medium in the
presence or absence of 17-AAG or NVP-AUY922 and seeded over a
0.6% agar base layer. After 14 days, cells were stained with
iodonitrotetrazolium violet and colonies greater than 100 μm were
analyzed with a visible light scanner (Image Scanner III; GEHealthcare,Buckinghamshire, United Kingdom) and software Image Quant TL
(GE Healthcare Europe GmbH, Freiburg, Germany).
Flow Cytometry
Cells were seeded and treated with 17-AAG or NVP-AUY922 for
24, 48, and 72 hours. Cells were trypsinized, washed with PBS, fixed
with 75% cold ethanol at −20°C for at least 1 hour, treated with 0.5%
Triton X-100 and 0.05% RNase A in PBS for 30 minutes, stained
with propidium iodide, and analyzed using a flow cytometer (BD
FACSCanto; Becton Dickinson & Co, Franklin Lakes, NJ) to
determine cell cycle distribution of DNA content.
Western BlotAnalysis
Cells were seeded, treated with DMSO, 17-AAG, or NVP-AUY922,
and lysed in a buffer containing 50 mM Tris (pH 7.4), 1% NP-40,
150 mM NaCl, 40 mM NaF, 1 mM Na3VO4, 1 mM PMSF, and
10 μg/ml protease inhibitor cocktail (Sigma-Aldrich). Protein determi-
nations were performed by the Bradford method (Bio-Rad, Richmond,
CA). Then, 50 to 80 μg of protein from each lysate was separated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis, transferred
to polyvinylidene difluoride membranes, blocked and incubated with
primary antibodies against EGFR, HER2, HER3, HER4, Akt, Hsp90,
Hsp70, Mdr-1, MRP1, BRCP1 and NQO1 from Santa Cruz
Biotechnology (Santa Cruz, CA), phospho-ERK1/2, ERK1/2, phos-
pho–ribosomal protein S6 (RPS6), and RPS6 from Cell Signaling
Technology (Danvers, MA), or β-actin (Sigma-Aldrich). Then,
membranes were incubated with HRP-linked secondary antibodies
from GEHealthcare and protein bands were detected using Pierce ECL
2 reagents (Thermo Scientific, Rockford, IL) and scanned with a
fluorescent light Typhoon 9410 scanner (GE Healthcare Europe
GmbH). Densitometric analyses were performed using Scion Image
software or Image Quant TL (GE Healthcare Europe GmbH).
Human Phospho-MAPK Arrays
Cells were seeded and treated with DMSO or 17-AAG (0.5 μM) or
NVP-AUY922 (0.1 μM) for 24 hours, lysed, and prepared according
to the manufacturer’s instructions of the Human Phospho-MAPK
Array Kit (R&D Systems, Minneapolis, MN). Protein concentrations
were determined by the Bradford method and 300 μg of each lysate
was diluted, mixed with biotinylated phospho-specific detection
antibodies, and incubated overnight on nitrocellulose membranes,
where capture and control antibodies have been previously spotted in
duplicate. After washing and removing unbound material, mem-
branes were incubated with streptavidin conjugated to HRP and
washed. Finally, the amount of phosphorylated protein bound in each
spot was detected by chemiluminescence. Membranes were incubated
with ECL reagents and scanned using a Typhoon 9410 scanner (GE
Healthcare Europe GmbH). The levels of phosphorylated proteins
were analyzed with the Image Quant TL (GE Healthcare Europe
GmbH) software and normalized to the levels of the control spots.
NQO1 Activity Assays
NQO1 specific activity was calculated using the DCPIP reduction
rate inhibited by dicumarol in cell extracts [36]. Cells were grown for
72 hours, lysed, and sonicated on ice in a buffer with 25 mM Tris-
HCl, pH 7.4, 250mM sucrose, and 5 μMflavin adenine dinucleotide.
Then, the NQO1 activity was measured in 10 μg of protein and
diluted in 1 ml with 25 mM Tris-HCl, pH 7.4, 0.7 mg/ml BSA, 200
μMNADH, and 40 μMDCPIP. Reactions were done in the absence
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determined in cells untreated or treated with 100 nM ES936 for 30
minutes or 4 hours and measured after 2 minutes at 600 nm using a
microplate reader (Infinite M200PRO NanoQuant).
Small-interfering (siRNA)-Mediated Inhibition of NQO1
Gene Expression
Cells were seeded and transfected with NQO1 siRNA (Ambion, Life
Technologies Corporation, Carlsbad, CA) or control siRNA (scrambled
sequence) (Santa Cruz Biotechnology), according to the manufacturer’s
instructions for 24 hours, using Opti-MEM I Reduced Serummedium
(Gibco, Life Technologies Corporation) and Lipofectamine RNAi-
MAX (Invitrogen, Life Technologies Corporation). Then, cells were
treated with DMSO or 17-AAG for 72 hours and harvested for
subsequent experiments.
Clonogenic Assays
Cells were counted and seeded in six-well plates in triplicate and at
a density of 1000 cells per well. After plating, cells were grown for 24
hours and some wells were pretreated with ES936 for 30 minutes.
Then, cells were washed with PBS and incubated with media
containing DMSO (vehicle), ES936, 17-AAG, or ES936 plus 17-
AAG, for 4 hours. Media with drugs were removed, cells were washed
with PBS again, fresh complete medium was added, and cells were
allowed to grow for 14 days. Finally, colonies formed were washed
with PBS, fixed with 4% formaldehyde, and stained with 0.05%
crystal violet for 30 minutes at room temperature. After that, the wells
were washed three times with deionized water and completely dried
for at least 30 minutes. The colonies were scanned with a visible light
scanner (Image Scanner III, GE Healthcare) and those with areas
greater than 100 μm were detected and counted with Image Quant
TL software (GE Healthcare Europe GmbH).
Analysis of Interaction between Two Compounds
Cells were seeded in 96-well plates and treated for 3 days using six
wells per treatment with suitable vehicle, different concentrations of
drugs (gemcitabine, oxaliplatin, AZD6244 (selumetinib), NVP-
BEZ235, or in combination with a single suboptimal concentration
of NVP-AUY922. Cell proliferation assays were performed as
described. The Bliss model [37,38] was used to determine whether
the combination of NVP-AUY922 with other drugs was additive,
synergistic, or antagonistic. A theoretical curve (bliss) was calculated
by using the following equation: Ebliss = EA + EB − EA × EB, where
EA and EB are the effects of drug A and drug B, respectively, expressed
as the fractional inhibition between 0 and 1. Eexperimental (Eexp) is the
actual result obtained by combination of both drugs. When Ebliss is
equal to Eexp, the combination is considered additive. If Ebliss is more
than Eexp the combination is synergistic. However, if Ebliss is less than
Eexp, the combination is antagonistic.
Statistical Analysis
The experiments were performed with n ≥ 3 and the data are
presented as means ± SEM. Statistically significant differences were
estimated from P b .05 and evaluated using the Mann-Whitney test.
The nonparametric two-tailed Spearman test was used to estimate the
correlation between NQO1 enzyme activity and 17-AAG or NVP-
AUY922 sensitivity. Statistical analyses were conducted using
GraphPad Prism version 4.0 (GraphPad Software Inc., San Diego,
CA) or SPSS version 10.0 (SPSS Inc, Chicago, IL).Results
17-AAG and NVP-AUY922 Effects in Anchorage-Dependent
and -Independent Growth
Wepursued the following experiments comparing the effects of 17-AAG
andNVP-AUY922. Proliferation of human pancreatic carcinoma cell lines
(IMIM-PC-2, RWP-1, BxPC3, Hs 766 T, HPAF-II, and IMIM-PC-1)
was inhibited in anchorage-dependent growth assays by 17-AAG.
Proliferation of CFPAC-1 and PANC-1 cells was inhibited only 41.3 ±
4.7% and 35.4 ± 4.5%, respectively, even at the maximum concentration
used of 2 μM(Figure 1A). However, colorectal carcinoma cell lines were in
general more sensitive to 17-AAG. The less 17-AAG-responsive LoVo and
Caco-2 colorectal cancer cell lines were growth inhibited only 28.3 ± 0.5%
and 28.1 ± 11.9%, respectively, at 0.5 μM but inhibited, respectively,
64.6 ± 10.6% and 54.94 ± 3.9% at higher concentrations (Figure 1B).
Colorectal carcinoma cell lines were in general more responsive also to
NVP-AUY922 than pancreatic carcinoma cell lines (Figure 1, C and D).
Anchorage-independent growth of IMIM-PC-1, HT-29, SW620, and
LoVo cells was inhibited after 17-AAG treatment (0.5 μM), whereas
PANC-1 and CFPAC-1 were also resistant to 17-AAG in soft agar assays
and anchorage-independent growth ofCaco-2 cells was only inhibited 50%
(Figure 2, A and B). The rest of the cells were also inhibited in anchorage-
independent growth assays after NVP-AUY922 treatment (0.1 μM).
Primary cultures from colorectal tumors were also inhibited by bothHsp90
inhibitors, even though the half maximal inhibitory concentration (IC50)
was higher than the IC50 of the cell lines. Interestingly, the primary culture
HCUVA-CC-34was inhibited only 43.8 ±4.4%with 17-AAGand40.4 ±
7.8% with NVP-AUY922 at the maximum concentration used of 10 μM
in anchorage-dependent growth assays (Figure 1, E and F). In addition,
anchorage-independent growth of the HCUVA-CC-34 primary cell
culture was moderately inhibited by 17-AAG and by NVP-AUY922 only
at the highest concentration used (Figure 2, C andD).
17-AAG and NVP-AUY922 Effects on Cell Cycle Distribution
of DNA Content
We performed cell cycle analyses and found that pancreatic carcinoma
IMIM-PC-2 cells accumulated in the G1 phase of the cell cycle upon 24
hours of 17-AAG or NVP-AUY922 treatment, followed by an
accumulation in the sub-G1 phase, indicative of cell death, after 48 or
72 hours of Hsp90 inhibitor treatment (Figure 3, A and C). However,
pancreatic carcinoma IMIM-PC-1 cells accumulated in theG2/Mphase of
the cell cycle, followed by an increase in the sub-G1 phase with both
inhibitors (Figure 3, A and C). The pancreatic cell line CFPAC-1
accumulated in theG2/Mphase and only slightly in sub-G1, and PANC-1
did not experience any change upon 17-AAG exposure (Figure 3A),
suggesting that both CFPAC-1 and PANC-1 cells are unresponsive to 17-
AAG but sensitive to NVP-AUY922 treatment. Conversely, when these
cells were treated with NVP-AUY922, they accumulated considerably in
the G2/M phase of the cell cycle followed by an increase in the sub-G1
phase (Figure 3C). Colorectal carcinoma cell lines HT-29 and SW620
accumulated in the G2/M and sub-G1 phases upon treatment with 17-
AAG or NVP-AUY922. Especially, the G2/M arrest induced by 17-AAG
treatment was very noticeable in HT29 cells (Figure 3, B and D). LoVo
cells mainly accumulated in the sub-G1 phase with both inhibitors,
whereas Caco-2 cells barely accumulated in theG2/Mphase with 17-AAG
but instead were arrested in this phase and also accumulated in sub-G1
after NVP-AUY922 treatment. This indicates that LoVo cells are sensitive
to 17-AAG and NVP-AUY922, but Caco-2 cells are practically
unresponsive to 17-AAG but sensitive to NVP-AUY922 treatment.
Figure 1. 17-AAG and NVP-AUY922 effects on cell proliferation. Pancreatic (A and C) and colorectal (B and D) carcinoma cell lines or
primary cell cultures obtained from colorectal tumors excised to patients (E and F) were treated with DMSO or different concentrations of
17-AAG (A, B, and E) or NVP-AUY922 (C, D, and F) for 72 hours. Cells were stained with crystal violet, proliferation rates were determined
by colorimetry, and the average of at least four experiments is represented and referred as percentage of control. Error bars are the SEM.
Each experiment was performed in sextuplicate (n = 6).
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Downstream of HER Receptors
To determine whether 17-AAG and NVP-AUY922 were able to
downregulate Hsp90 protein clients such as EGFR family members, we
performedWestern blot analyses and found that indeed EGFR andHER2
down-regulation could be detected within 4 hours of 17-AAG treatment
in sensitive cell lines but not in cell lines resistant to 17-AAG (Figure 4A).
In addition, EGFR and HER2 receptors were even more efficiently
downregulated within 4 hours of NVP-AUY922 exposure (Figure 4A).
Moreover, EGFR, HER2, HER3, and HER4 protein steady-state levels
were depleted in the 17-AAG–sensitive pancreatic (Figure 4B) and
colorectal cell lines (Figure 5A) within 24 hours of 17-AAG treatment and
in all cell lines afterNVP-AUY922 treatment. The small decrease observed
in HER2 or HER3 protein levels in some 17-AAG–resistant cells was not
enough to shut down the downstream signaling pathway, as ERK1/2
phosphorylation was unaltered. EGFR, HER4, and Akt protein levels
were unaffected in 17-AAG–resistant cells. However, Akt steady-state
protein levels and ERK1/2 phosphorylation levels decreased in sensitive
cell lines, indicating that signaling pathways downstreamofHER receptorswere affected by 17-AAG treatment. Likewise, NVP-AUY922 treatment
caused depletion of EGFR,HER2andHER3 receptors, Akt, andERK1/2
inactivation in all cell lines tested. HER4 receptor was barely
downregulated in Caco-2 cells, but still the downstream signaling was
interrupted. Hsp70, the hallmark of inhibition of Hsp90 function, was
upregulated in 17-AAG–sensitive cell lines in all cell lines within 4 hours of
exposure to both drugs (Figure 4A), and only slightly upregulated in some
17-AAG–resistant cell lines at later time points (Figure 5A). In addition,
EGFR was downregulated in primary colorectal cell cultures, as Hsp70
levels were augmented, except in theHCUVA-CC-34 primary cell culture
after 0.1 μM NVP-AUY922 exposure. ERK1/2 phosphorylation levels
decreased after 17-AAG exposure and only in the more NVP-AUY922–
sensitive cultures after treatment with this drug (Figure 5B). EGFRprotein
levels were undetected in SW620 cells and HCUVA-CC-1 primary
culture. Hsp90 levels were unaltered upon 17-AAG or NVP-AUY922
treatment (Figures 4 and 5). To further determine the effects of Hsp90
inhibitors on the phosphorylation of these and other important signaling
molecules downstream of HER receptors, we performed phospho-kinase
arrays and found that the phosphorylation levels of the three Akt isoforms
Figure 2. Effects of 17-AAG andNVP-AUY922 on colony formation. Pancreatic cancer cell lines IMIM-PC-1, PANC-1, and CFPAC-1 (A) or colorectal
carcinomacell linesHT-29,SW620,LoVo, andCaco-2 (B)wereseededoveragarplates in thepresenceofDMSO(control), 0.5μM17-AAG,or0.1μM
NVP-AUY922.Colorectal cancerprimaryculturesHCUVA (CandD)wereseededoveragarplates in thepresenceofDMSO(control), 0.5μM17-AAG,
2 μM 17-AAG, 0.1 μMNVP-AUY922, or 1 μMNVP-AUY922. Colonies were stained and counted after 14 days. Each treatment was performed in
triplicate and error bars are the SEM. Difference between means was statistically significant (*P b .05, Mann-Whitney test).
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compared to control levels in IMIM-PC-2 cells, except for the Akt2
isoform upon NVP-AUY922 treatment whose phosphorylation levels
were unaltered. In addition, the decrease in phosphorylation of ERK1/2
upon exposure to both drugs was confirmed. Interestingly enough, p70S6
kinase (p70S6k) and p90S6 kinase (RSK1) phosphorylation levels also
diminished upon 17-AAG andNVP-AUY922 treatment (Figure 6,A and
B). The phosphorylation levels of RPS6, the target of p70S6k, which is
downstream of Akt, were inhibited in IMIM-PC-2 andHT-29 cells, only
slightly in Caco-2 and not affected in PANC-1 cells by 0.5 μM 17-AAG.
However, RPS6 phosphorylation levels decreased in all cell lines tested
after 0.1 μM NVP-AUY922 treatment (Figure 6C).
Role of ABC Transporters in 17-AAG Intrinsic Resistance
Since MDR is frequently associated with overexpression of ABC
transporters, we wanted to determine whether these ABC transporters
were involved in the intrinsic resistance to 17-AAG observed in these
cell lines. We found that none of the pancreatic carcinoma cell lines
used expressed Mdr-1 (Pgp) protein (Figure 7). However, the
colorectal carcinoma cell lines HCT-15, DLD-1, LS 174 T, and
LoVo cells that express Mdr-1 are growth inhibited by 17-AAG. We
used Colo 320 cells as a positive control for Mdr-1 expression. MRP1
expression could be barely detected only in DLD-1 cells, which
respond to 17-AAG. T98G cells were used as a positive control. On
the contrary, BCRP1 expression was detected mainly in the sensitive
Hs 766 T pancreatic carcinoma cells and to a lesser extent in severalcolorectal carcinoma cell lines: DLD-1, SW480, LS 174 T, SW620,
HCT-15, and HGUE-C-1 sensitive to 17-AAG and in Caco-2 cells
resistant to 17-AAG. The 17-AAG–resistant PANC-1 and CFPAC-1
cells do not express any of the ABC transporters used in our study.
NQO1/DT-Diaphorase Expression and Enzymatic Activity
We wanted to confirm whether NQO1 was involved in the intrinsic
resistance to 17-AAG found by others in pancreatic cancer cell lines [39]
and to determine its role in our panel of pancreatic and colorectal
carcinoma cell lines and primary tumor cell cultures. The protein NQO1
levels and enzymatic activity were undetectable in the 17-AAG–resistant
CFPAC-1 and PANC-1 pancreatic carcinoma cells and in Caco-2
colorectal cells, which are 17-AAG–resistant (Figure 8, A and B). In fact,
there was a negative correlation between the IC50 for 17-AAG after 72
hours of drug exposure and NQO1 activity in the pancreatic and
colorectal carcinoma cells studied (Figure 8C). In addition, the primary
cell cultures derived from colorectal tumors express different levels of
NQO1 andHsp70 (Figure 8A). Interestingly, NQO1 protein levels were
relatively high in the less sensitive primary culture to both 17-AAG and
NVP-AUY922, HCUVA-CC-34. As expected, there was no correlation
between the IC50 for NVP-AUY922 and NQO1 enzymatic activity in
the pancreatic and colorectal carcinoma cell lines studied (Figure 8C).
Pharmacological Inhibition of NQO1
To determine the role of NQO1 in sensitivity to 17-AAG, we
performed cell proliferation assays in 17-AAG–sensitive cell lines in
Figure 3. 17-AAG and NVP-AUY922 effects on cell death. (A and C) Pancreatic cell lines IMIM-PC-2, IMIM-PC-1, CFPAC-1, and PANC-1 and
(B and D) colorectal cell lines HT-29, SW620, LoVo, and Caco-2 were grown and treated with DMSO, 0.5 μM 17-AAG (A and B), or 0.1 μM
NVP-AUY922 (C and D) for 24, 48, or 72 hours, and cell cycle distribution of DNA content was determined by flow cytometry. The sub-G1
phase, indicative of cell death, is represented as percentage of control and is the average of at least three separate experiments.
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dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione], which was
added 30 minutes before exposure to 17-AAG and sustained
throughout 17-AAG treatment for 72 hours. In spite of significantly
reducing NQO1 activity (Figure 8B), this inhibitor was unable toconfer 17-AAG resistance to sensitive cells (Figure 9A). As expected,
no effect was observed in cell lines devoid of NQO1 protein or
enzymatic activity, such as CFPAC-1, PANC-1, or Caco-2 cells (data
not shown). Then, we wanted to determine the effects of NQO1
ablation in long-term clonogenic assays. First, we determined that
Figure 4. Hsp90 inhibitor effects onHsp90 client proteins, Hsp70, and
Hsp90 in pancreatic cancer cells. (A) Pancreatic cancer IMIM-PC-2 and
PANC-1 cellswere grown, left untreated (−), or treated (+)with 0.5 μM
17-AAG for 4, 8, or 16 hours. Pancreatic cancer IMIM-PC-1 or CFPAC-1
cells were grown, left untreated (−), or treated (+) with 0.1 μM NVP-
AUY922 for 4, 8, or 16 hours. Cell extractswere obtained and analyzed
by Western blot using EGFR, HER2, Hsp70, Hsp90, and β-actin
antibodies. (B) Pancreatic carcinoma IMIM-PC-2 and PANC-1 cells
were grown, left untreated (−), or treated (+) with 0.5 μM 17-AAG for
24 or 48 hours. Cell extracts were obtained and analyzed by Western
blot using EGFR, HER2, HER3, HER4, Akt, phospho-ERK1/2, ERK1/2,
Hsp70, Hsp90, and β-actin antibodies. In all the experiments, β-actin
was used as a loading control.
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inhibited (Figure 9D). Then, we performed clonogenic experiments
after incubating HT-29 cells for 4 hours with 17-AAG or acombination of the specific inhibitor ES936 and 17-AAG and found
that clonogenic survival of cells was only slightly recovered after the
combination treatment (Figure 9, B and C).
Biologic Inhibition of NQO1
Since reexpression of NQO1 in PANC-1 cells devoid of this enzyme
has already been performed [39], we wanted to determine whether the
silencing of NQO1 would render resistance to sensitive cells. To do
that, we used a biologic approach to knock down NQO1 by using a
specific siRNA targeted against NQO1 in the 17-AAG–sensitive
IMIM-PC-2 cells. Both NQO1 protein levels and enzymatic activity
were abolished (Figure 10, A and C), and still the proliferation of
IMIM-PC-2 cells was inhibited by 17-AAG to the same extent as in the
nontransfected cells or in the cells transfected with scrambled siRNA
(Figure 10B), indicating that 17-AAG is effective even in the absence of
NQO1. Furthermore, Hsp70 protein levels increased and EGFR
protein levels decreased on 17-AAG treatment in IMIM-PC-2 cells
devoid of NQO1 (Figure 10A).
Combination of NVP-AUY922 with Other Drugs
After demonstrating that NVP-AUY922 is more efficacious than
17-AAG in our cellular models, we set out to determine whether this
drug was able to potentiate the effects of chemotherapeutic drugs
currently in the clinic, such as gemcitabine for pancreatic cancer and
oxaliplatin for colorectal cancer. Additionally, we tested the effect of
combining NVP-AUY922 with the Mek inhibitor AZD-6244
(selumetinib) and with the dual phosphatidylinositol 3-kinase/
mammalian target of Rapamycin inhibitor NVP-BEZ235. The
effects of various concentrations of these antitumor drugs with a
single concentration of NVP-AUY922 are depicted in Figure 11. We
selected cell lines that were nonresponsive to such drugs, according to
unpublished data from our laboratory. Suboptimal concentrations of
NVP-AUY922 were synergistic (Ebliss N Eexp) with gemcitabine in the
CFPAC-1 (Figure 11A) and PANC-1 (Figure 11B) pancreatic cancer
cells, with oxaliplatin in the HCT-15 colorectal cancer cells
(Figure 11C), with AZD6244 in DLD-1 colorectal cancer cells
(Figure 11D), and with NVP-BEZ235 in the pancreatic carcinoma
PANC-1 cells (Figure 11E).Discussion
The use of Hsp90 inhibitors has emerged as a potential antitumor
therapy. Exocrine pancreatic adenocarcinoma has a very poor
prognosis. In addition, colorectal carcinoma is one of the most
common types of cancer. HER receptors and their downstream
signaling are very important in these types of cancer. Therefore, we
were interested in using Hsp90 inhibitors able to downregulate HER
receptors as a therapeutic strategy in pancreatic and colorectal
carcinomas. As a matter of fact, 17-AAG is being studied in phase I
and phase II clinical trials for a variety of solid tumors with promising
results, especially in HER2+ breast cancer and multiple myeloma [3]
and in combination with therapeutic agents such as Herceptin and
Vortezomib [40]. Furthermore, although numerous clinical trials
with 17-AAG have already been completed or terminated, IPI-504
(retaspimycin), the water-soluble hydroquinone derivative of 17-
AAG [41], is currently being evaluated in several clinical trials (see
http://www.clinicaltrials.gov/ct2/results?term=17-AAG&Search=
Search). However, the isoxazole derivative NVP-AUY922 is able to
deplete HER2 in breast cancer cells [13] and EGFR in non–small
lung cancer cells [42] and is also under clinical evaluation for the
Figure 5. Hsp90 inhibitor effects on Hsp90 client proteins, Hsp70, and Hsp90 in colorectal cancer cells. (A) Colorectal carcinoma HT-29
and Caco-2 cells were grown, left untreated (−), or treated (+) with 0.5 μM 17-AAG for 24 or 48 hours. (A) Colorectal carcinoma SW620
and Caco-2 cells were grown, left untreated (−), or treated (+) with 0.1 μM NVP-AUY922 for 24 or 48 hours. Cell extracts were obtained
and analyzed by Western blot using EGFR, HER2, HER3, HER4, Akt, phospho-ERK1/2, ERK1/2, Hsp70, Hsp90, and β-actin antibodies.
(B) Primary cultures HCUVA derived from colorectal tumors excised to patients were grown, left untreated (−), or treated with 0.5 μM 17-
AAG (+), 2 μM 17-AAG (++), 0.1 μM NVP-AUY922 (×), or 1 μM NVP-AU922 (××). Cells extracts were analyzed using antibodies against
EGFR, phospho-ERK1/2, ERK1/2, Hsp70, Hsp90, and β-actin antibodies. β-Actin was used as a loading control.
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ct2/results?term=AUY922&Search=Search). Other Hsp90 small
molecule inhibitors under current clinical evaluation include
AT13387, STA9090, and MPC3100. In particular, STA-9090
(ganetespib) is being evaluated over 25 clinical trials, including breast,
lung, colorectal, and hematologic tumors (http://www.clinicaltrials.
gov/ct2/results?term=ganetespib&pg=1). In this report, we have used
a panel of pancreatic and colorectal carcinoma cell lines and primary
cultures derived from human tumors to test the effects of 17-AAG
and NVP-AUY922. In addition, we were interested in finding
molecular determinants of sensitivity or resistance to these drugs. We
have determined that pancreatic carcinoma PANC-1 and CFPAC-1
cells were resistant to 17-AAG both in anchorage-dependent and
-independent growth assays (Figures 1 and 2). The colorectal
carcinoma cell line Caco-2 was also resistant to 17-AAG (Figure 1).Pancreatic and colorectal sensitive cell lines underwent cell death
upon 17-AAG treatment, as indicated by an increase in the sub-G1
phase of the cell cycle, whereas resistant cell lines did not (Figure 3).
However, all cell lines were sensitive to NVP-AUY922. A previous
report has shown that NVP-AUY922 is able to inhibit migratory and
invasive properties of pancreatic cancer cells [43]. However, when we
performed anchorage-dependent and -independent growth assays in
primary cultures obtained from colorectal tumors, we found that the
HCUVA-CC-34 was not very responsive to 17-AAG and even less
responsive to NVP-AUY922. We have demonstrated in this report
that EGFR, HER2, HER3, and HER4 are Hsp90 client proteins that
are depleted upon 17-AAG treatment in sensitive pancreatic and
colorectal cell lines such as IMIM-PC-1, IMIM-PC-2, SW620, or
HT-29 but not in resistant PANC-1, CFPAC-1, or Caco-2 cells
within 4 or 8 hours (Figures 4 and 5 and data not shown). Not only
Figure 6. Hsp90 inhibitor effects on different kinases and RPS6
phosphorylation levels. Phospho-MAPK array (A) IMIM-PC-2 pancre-
atic cells were grown and treated with DMSO (control) or 0.5 μM17-
AAG. Cell extracts were subjected to the human phospho-MAPK
array, as described in the Materials and Methods section. The graph
represents relative phosphorylation levels of the most relevant
kinases: Akt1 Ser473), Akt2 (Ser474), Akt3 (Ser472), Akt pan (Ser473,
Ser474, and Ser472), p70S6k (Thr421/Ser424), ERK1 (Thr202/
Tyr204), ERK2 (Thr185/Tyr187), and RSK1 (Ser380) in treated cells
compared to nontreated cells (control). (B) IMIM-PC-2 pancreatic
cells were grown and treated with DMSO (control) or 0.1 μM NVP-
AUY922 for 24 hours and analyzed using the human phospho-MAPK
array. The graph represents relative phosphorylation levels of
relevant kinases as in (A). RPS6phosphorylation levels. (C) Pancreatic
cancer IMIM-PC-2 and PANC-1 and colorectal carcinoma HT-29 and
Caco-2 were grown, left untreated (−), or treated (+) with 0.5 μM17-
AAG. In the sameway, pancreatic cancer IMIM-PC-2, IMIM-PC-1, and
CFPAC-1 cells and colorectal carcinoma Caco-2 cells were grown,
left untreated (−), or treated (+) with 0.1 μM NVP-AUY922 for 24
hours. Cell extracts were obtained and analyzed by Western blot
using phospho-RPS6, RPS6, and β-actin antibodies. β-Actin was
used as a loading control.
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of tyrosine kinase receptors were also downregulated in sensitive cell
lines, since Akt protein levels, Akt, RSK1, p70S6k, RPS6, and ERK2
phosphorylation levels diminished upon 17-AAG treatment (Fig-
ures 4–6). Albeit HER2 and HER3 protein levels were partially
downregulated by 17-AAG in some of the resistant cells, the signaling
pathways in these cells were unaltered. NVP-AUY922 was also able to
deplete HER receptors in all cell lines tested within 4 or 8 hours
(Figures 4 and 5 and data not shown). The induction of Hsp70
was observed in sensitive cell lines to 17-AAG very rapidly, within 4
or 8 hours of treatment. The slight increase in Hsp70 and down-
regulation of some protein clients that we observed in some cases in
resistant cell lines could be due to the fact that 17-AAG binds poorlyto the Hsp90 complex and has some inhibitory capacity that is not
translated into cell growth inhibition or cell death. As all cell lines
respond to NVP-AUY922, the increase in Hsp70 is very significant
and occurs rapidly. In the HCUVA-CC-34 primary culture however,
EGFR depletion, ERK1/2 phosphorylation, and Hsp70 up-regula-
tion are not very dramatic, which explain the moderate effects of this
drug in anchorage-dependent and anchorage-independent growth
assays. Experiments are underway to try to identify a possible
mechanism of resistance of HCUVA-CC-34 and other colorectal
cellular models to NVP-AUY922.
Since all our cellular models, apart from the exception just
mentioned, were sensitive to NVP-AUY922, we sought to find
markers of sensitivity/resistance to 17-AAG. In fact, phospho-kinase
arrays were performed in 17-AAG–sensitive as well as in 17-AAG–
resistant cell lines with the intention to find putative markers.
However, we could not clearly associate differences found between
cell lines to resistance to this drug. As it has been suggested that ABC
transporters may play a role in resistance to Hsp90 inhibitors, we
analyzed Mdr-1, MRP1, and BRCP1 protein levels in these cell lines
and found that none of the 17-AAG–resistant pancreatic and
colorectal carcinoma cell lines expressed these transporters, with the
exception of Caco-2 cells that express very low levels of BRCP1.
However, many of the 17-AAG–sensitive cell lines express some of
these ABC transporters (Figure 7). Therefore, we can rule out the role
of these ABC transporters in 17-AAG resistance. In addition to Pgp
(Mdr-1), it has been suggested in several reports that NQO1/DT-
diaphorase is necessary for benzoquinone ansamycin function. This
enzyme is able to metabolize quinones to the corresponding
hydroquinones, which are more stable and bind Hsp90 with greater
affinity. We have found that the 17-AAG–resistant pancreatic
carcinoma PANC-1 and CFPAC-1 cells lack NQO1 protein and
activity (Figure 8), confirming the results previously reported by
Siegel et al. [39]. The 17-AAG–resistant Caco-2 cells also lack NQO1
protein and enzymatic activity. However, LoVo cells, which are also
devoid of NQO1 enzyme (Figure 8), are still responsive to 17-AAG,
as demonstrated especially in soft agar assays and cell cycle analyses
(Figures 2 and 3). We speculate that other reductases, albeit with less
potency, may be able to reduce 17-AAG to 17-AAGH2 in these cells.
Figure 7. Expression of ABC transporters. Pancreatic and colorectal cells were grown, lysed, and subjected to Western blot analyses to
detect basal levels of Mdr-1, MRP1, BRCP1, or β-actin, using specific antibodies. Colo 320 and T98G cell extracts were used as positive
controls. β-Actin was used as a loading control. Densitometric values of the ratio between ABC transporters and β-actin are indicated.
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benzoquinones may also have an activity and be able to exert the
same effects as their reduced counterparts at higher concentrations.
When we blocked NQO1 activity in 17-AAG–sensitive cell lines
with ES936, these cells were still growth inhibited by 17-AAG
(Figure 9). Furthermore, knocking down NQO1 with siRNA did
not confer 17-AAG resistance to the pancreatic carcinoma IMIM-
PC-2 (Figure 10), IMIM-PC-1 cells, and the colorectal carcinoma
HT-29 and SW620 cells (data not shown), indicating that NQO1
activity is dispensable in these cellular models for 17-AAG action.
Increased levels of pro-survival chaperones such as Hsp27 [44] and
Hsp70 due to elevation in the heat shock response [45] have been
proposed as possible NQO1-unrelated causes of resistance to
benzoquinone ansamycins [46]. In our system however, Hsp70
protein levels were not significantly induced after 17-AAG
treatment in resistant cells. Inaccessibility of Hsp90 inhibitors to
the Hsp90 isoforms located in mitochondria [47], which contribute
to apoptosis inhibition, may be another plausible cause of resistance.
Furthermore, mutations or alterations in posttranslational modifi-
cations in the Hsp90 itself may contribute to Hsp90 inhibitor
resistance [46]. Our cellular models, however, were sensitive to
NVP-AUY922, which is based on resorcinol and not structurally
related to benzoquinones [14]. This inhibitor is not dependent on
the presence of NQO1 and we have demonstrated that NVP-
AUY922 sensitivity does not correlate with NQO1 activity
(Figure 8C). In a clinical setting, it is more useful to use NVP-
AUY922 that offers several advantages over benzoquinones: no liver
toxicity and no NQO1 or other reductase requirement for its
function. Furthermore, we have shown in this report for the first
time that this novel Hsp90 inhibitor is very potent in combination
with other drugs such as gemcitabine, oxaliplatin, AZD6244, or
NVP-BEZ235 in cell lines that are not very responsive to these drugs
(Figure 11). Moreover, it has been shown that NVP-AUY922 is able
to sensitize prostate cancer cell to radiation [48]. Therefore, NVP-
AUY922 has a great potential to be used not only as a single agent
but also in combination with chemotherapy or radiation therapy,
even when these agents are not very effective when used alone.Conclusions
NVP-AUY922 is a more potent inhibitor than 17-AAG in pancreatic
and colorectal cellular models, as demonstrated by inhibition of cell
proliferation and colony formation, cell death induction, HER
receptor depletion, and inhibition of ERK and Akt signaling
pathways. Some of these models show resistance to 17-AAG,
especially pancreatic carcinoma cell lines. The ABC transporters
examined are not involved in resistance to the Hsp90 inhibitors 17-
AAG and NVP-AUY922. The use of NQO1 as a biomarker of
response to Hsp90 inhibitors is limited only to 17-AAG and not to
NVP-AUY922 and is dependent on the cellular context. Moreover,
we show that rather than a marker of response to 17-AAG, NQO1 is
a marker of sensitivity, as cells devoid of this enzyme can still respond
to 17-AAG. Therefore, the utilization of non-benzoquinone
compounds such as NVP-AUY922 is more appropriate. In fact,
NVP-AUY922 is being clinically evaluated both as a single agent and
in combination with other antineoplastic drugs or radiation and
represents a promising novel therapeutic strategy for the treatment of
solid malignancies such as pancreatic and colorectal carcinomas.
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